Ummekalsoom Malik, MD
Hematology & Oncology · Lake Success, NYNPI 1124021209
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (49.8%), food and beverage and education — rather than concentrated in one kind of arrangement. 11 manufacturers reported payments, led by Puma Biotechnology, Inc. at 54.8% of the total. Reporting peaked in 2019 at $1,575 and has fallen 84.4% since, to $246 in 2025. That places this record below the midpoint for hematology & oncology clinicians in NY, where the typical reported total is $1,337.
Across 28 payments — averaging $71.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Puma Biotechnology, Inc.$1K
- Novartis$362
- Merck$127
- Incyte Corporation$125
- Lilly USA, LLC$109
- E.r. Squibb & Sons, L.L.C.$66
- plus $118 from 5 others
What the payments were for
- Consulting fees$1,00050%
- Food & beverage$89945%
- Education$1095%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Puma Biotechnology, Inc. | 2 | $1,101 |
| Novartis | 13 | $362 |
| Merck | 2 | $127 |
| Incyte Corporation | 1 | $125 |
| Lilly USA, LLC | 1 | $109 |
| E.r. Squibb & Sons, L.L.C. | 4 | $66 |
| Sanofi | 1 | $29 |
| GSK | 1 | $27 |
| Bristol Myers Squibb | 1 | $26 |
| Myriad Genetic Laboratories, Inc. | 1 | $23 |
| AstraZeneca | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,008 in reported general payments places this provider in the 50th percentile of 967 hematology & oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 15 | $18,813 |
| Hydroxyurea | 25 | $621 |
| Dexamethasone | 11 | $332 |
| Letrozole | 13 | $174 |
| Famotidine | 12 | $21 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Lake Success
- Francis ArenaLake Success$1M
- Michael SchusterNew York$1.6M
- Charles SawyersNew York$1.6M
- Manuel Hidalgo-MedinaNew York$1.4M
- Sanjeev JainEast Patchogue$971K
- Ross LevineNew York$968K
- Perry CookBrooklyn$803K
- Mihir RavalAlbany$767K
- Joshua SabariNew York$761K
- Gail RobozNew York$738K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.